Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

Area of Science:

• Immunology
• Otolaryngology
• Pulmonology

Background:

• Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life.
• Current treatments may not provide sufficient relief for all patients.
• Dupilumab targets the IL-4/IL-13 pathway, implicated in CRSwNP pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of dupilumab in improving patient-reported symptoms and objective outcomes in CRSwNP.
• To assess clinically meaningful within-patient changes from baseline in response to dupilumab treatment.
• To analyze data from the SINUS-24 and SINUS-52 clinical trials.

Main Methods:

• Post hoc analysis of patients with CRSwNP receiving dupilumab or placebo every 2 weeks.
• Daily recording of nasal congestion, loss of smell, and rhinorrhea severity.
• Objective measures included the University of Pennsylvania Smell Identification Test (UPSIT), nasal polyp score (NPS), and Lund-Mackay CT score (LMK-CT).

Main Results:

• Dupilumab treatment resulted in significantly higher responder rates compared to placebo across all assessed outcomes at week 24.
• Clinically meaningful improvements were observed in nasal congestion, loss of smell, total symptom score, UPSIT, NPS, and LMK-CT.
• These positive results were consistent at week 52 of treatment.

Conclusions:

• Dupilumab demonstrates significant efficacy in treating CRSwNP.
• The treatment leads to clinically meaningful improvements in both subjective and objective measures of the disease.
• Dupilumab represents an effective therapeutic option for patients with CRSwNP.